RNhale GmbH is a spin-off originating from the Ludwig-Maximilians-University Munich, aiming to revolutionize the pharmaceutical landscape by developing a unique platform technology for formulating RNA-loaded lipid nanoparticles (LNPs) as an inhalable dry powder. This disruptive approach synergizes technological and pharmaceutical strategies to create a novel therapeutic formulation with significant advantages over common LNP-RNA delivery methods. The target is pulmonary diseases with vast addressable markets and undeniable medical needs.

rnhale

Org chart

Teams

Offices